RxDoctor Payments Data

Juan Cordero, MD

Cardiovascular Disease · Easton, MDNPI 1740224245

Payments from drug & device makers

$1,775in general payments, 2019–2025

Across 73 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$472
  • Amgen$250
  • Pfizer$225
  • Novartis$188
  • AstraZeneca$135
  • Aroa Biosurgery Incorporated$134
  • plus $370 from 9 others

What the payments were for

  • Food & beverage$1,76199%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,775 in reported general payments places this provider in the 50th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$628,196
Medicare patients
1,313
Services billed
5,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban951$816,729
XareltoRivaroxaban381$384,915
EntrestoSacubitril/Valsartan280$232,975
JardianceEmpagliflozin151$110,672
Repatha SyringeEvolocumab85$51,490
Repatha SureclickEvolocumab66$46,599
FarxigaDapagliflozin Propanediol50$36,498
MultaqDronedarone Hcl18$28,703
Rosuvastatin Calcium618$13,255
Praluent PenAlirocumab24$12,610
Metoprolol Succinate814$12,181
Ezetimibe193$10,277
Dabigatran EtexilateDabigatran Etexilate Mesylate24$6,807
Atorvastatin Calcium491$6,202
Valsartan183$5,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$225$816,729951 claims
Johnson & JohnsonXarelto$103$384,915381 claims
NovartisEntresto$188$232,975280 claims
AstraZenecaFarxiga$135$36,49850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Easton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →